title: Adaptability of structured forms for CSII initiation in patients with type 2 diabetes the Getting2Goal(SM) concept.
abstract: BACKGROUND
  The goal is to assess the usability and satisfaction of implementing the Getting2Goal(SM) protocol by physicians transitioning patients with type 2 diabetes (T2DM) from multiple daily injections (MDI) to continuous subcutaneous insulin infusion (CSII).
  
  
  METHODS
  T2DM patients from three diabetes clinics were switched from MDI to CSII. Physicians used the Getting2Goal type 2 pumping protocol to prescribe and manage insulin pump therapy for T2DM. Surveys were conducted in which the physicians rated their feedback related to acceptability of the Getting2Goal on a 5-point Likert scale.
  
  
  RESULTS
  17 patients with T2DM were switched from MDI to CSII treatment. Mean (±standard deviation) age was 61.2 ± 7.7 (46-77) years, weight was 91.4 ± 21 (66-147) kg, BMI was 31.9 ± 7.6, A1C was 9.2 ± 1.4 % (7.2-12.3) and TDD on MDI was 109.1 ± 53.1 units. Surveys completed by physicians indicated Getting2Goal type 2 pumping protocol to be more efficient, time saving, and structured compared to their current processes. In addition, the primarily prescribed TDD on pump was 98.1 ± 50.0 units and the TDD at first download was 81.4 ± 36.4 units, representing a 25.4 % reduction in TDD At first download. The percentage of all blood glucose readings below 70 mg/dL was also very low.
  
  
  CONCLUSIONS
  The data indicate Getting2Goal materials as a standard approach that is simple and efficient to initiate pump therapy for T2DM. At the same time, it is safe and a useful tool for physicians that are starting to prescribe pump therapy for T2DM.
authors.affiliation: Sackler School of Medicine, Ch. Sheba Medical Center, Institute of Endocrinology, Tel Hashomer, Tel Aviv University, 52621, Tel Aviv, Israel. ohdcohen@sheba.health.gov.il.
authors.forename: O
authors.initials: O
authors.lastname: Cohen
authors.affiliation: Cllalit Health Services, Tel Aviv, Israel.
authors.forename: Z
authors.initials: Z
authors.lastname: Agabria
authors.affiliation: Diabetes Clinic, Maccabi Health Service, Rehovot, Israel.|Endocrinology and Metabolism Clinic, Kaplan Medical Center, Rehovot, Israel.
authors.forename: L
authors.initials: L
authors.lastname: Lysyy
authors.affiliation: Diabetes Clinic, Maccabi Health Service, Ashkelon, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Ianovitsky
authors.affiliation: Medtronic, Inc., Northridge, CA, USA.
authors.forename: X
authors.initials: X
authors.lastname: Nguyen
authors.affiliation: Medtronic, Inc., Northridge, CA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Fung
authors.affiliation: Medtronic, Inc., Northridge, CA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.affiliation: Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.
authors.forename: J
authors.initials: J
authors.lastname: Wainstein
mesh_terms: D000222:Adaptation, Physiological; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D055104:Infusions, Subcutaneous; D007328:Insulin / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
keywords: CareLink; Continuous subcutaneous insulin infusion; Total daily dose; Type 2 diabetes